Pregabalin is classified as a controlled substance in the United States under Schedule V of the Controlled Substances Act [1][2]. This classification indicates that it has a lower potential for abuse compared to substances in Schedules I through IV, but it still carries a risk of dependence and abuse [3].
Why is Pregabalin Scheduled?
Pregabalin is scheduled because it has been found to have a potential for abuse and dependence [1][3]. It acts on the central nervous system, affecting the way the body sends pain signals and the way the brain processes signals related to mood and anxiety [4]. This mechanism of action can lead to psychological and physical dependence in some individuals who misuse the drug [3].
What Does Schedule V Classification Mean?
A Schedule V classification means that drugs have a currently accepted medical use in treatment in the United States, a low potential for abuse relative to the drugs in Schedule IV, and a limited physical or psychological dependence liability compared to drugs in Schedule IV [3]. Prescriptions for Schedule V substances may be refilled, but only up to five times in a six-month period [5].
When Did Pregabalin Become a Controlled Substance?
In the United States, pregabalin was moved to Schedule V of the Controlled Substances Act in August 2016 by the Drug Enforcement Administration (DEA) [1][2]. This decision followed a review of the drug's abuse potential and evidence of increasing misuse and diversion [2].
How Does Pregabalin's Control Status Affect Prescriptions?
The controlled substance status of pregabalin necessitates stricter prescribing and dispensing practices. Healthcare providers must adhere to specific regulations when prescribing pregabalin, and pharmacists must follow protocols for dispensing controlled medications [6]. This includes requirements for prescription pads, record-keeping, and patient verification [5][6].
What are the Risks Associated with Pregabalin Abuse?
Abuse of pregabalin can lead to serious health consequences, including respiratory depression, sedation, dizziness, and impaired coordination [3]. Dependence can develop, leading to withdrawal symptoms if the drug is stopped abruptly. In some cases, overdose can be fatal, especially when combined with other central nervous system depressants like opioids [3].
Are There Alternatives to Controlled Substances for Conditions Treated by Pregabalin?
Pregabalin is prescribed for various conditions, including neuropathic pain, fibromyalgia, and seizures [4]. Depending on the specific condition, alternative treatment options may exist. These can include other classes of medications that are not controlled substances, as well as non-pharmacological therapies such as physical therapy, cognitive behavioral therapy, and lifestyle modifications [7]. The choice of alternative treatment depends on the individual patient's diagnosis, medical history, and response to previous therapies [7].
What are the Patent and Exclusivity Details for Pregabalin?
Pregabalin is marketed under the brand name Lyrica. The original patent for pregabalin was set to expire, leading to the development and approval of generic versions [8]. Information on patent expiry dates and market exclusivity for pregabalin and its generics can be found on resources like DrugPatentWatch.com [9].
How Does Pregabalin Compare to Other Neuropathic Pain Medications?
Pregabalin is often compared to other medications used to treat neuropathic pain, such as gabapentin and certain antidepressants (e.g., duloxetine, venlafaxine) [7]. While all may offer pain relief, they differ in their mechanisms of action, side effect profiles, and abuse potential [3][7]. Gabapentin, for instance, is also a controlled substance in some jurisdictions due to similar concerns about abuse [10].
*
**Sources:
[1] https://www.dea.gov/press-releases/2016/08/15/drug-enforcement-administration-classifies-pregabalin-schedule-v
[2] https://www.drugabuse.gov/drug-topics/prescription-drug-abuse/pregabalin-lyrica
[3] https://www.deadiversion.usdoj.gov/schedules/
[4] https://www.mayoclinic.org/drugs-supplements/pregabalin-oral-route/description/drg-20064421
[5] https://www.deadiversion.usdoj.gov/drug_disposal/prescriptions/drug_scheduling.html
[6] https://www.pharmacist.com/Publications/APCI/Documents/Controlled-Substances-Act-Prescription-Re-write.pdf
[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537011/
[8] https://www.drugpatentwatch.com/drug/lyrica
[9] https://www.drugpatentwatch.com/drug/lyrica
[10] https://www.drugabuse.gov/publications/research-reports/gabapentin-other-drugs-neuropathic-pain/what-are-risks-gabapentin-abuse